SPX3,693.23-64.76 -1.72%
DIA295.86-4.66 -1.55%
IXIC10,867.93-198.88 -1.80%

BRIEF-Sagimet Biosciences Announces Completion Of Patient Enrollment In Phase 2B 'Fascinate-2' Clinical Trial

BRIEF-Sagimet Biosciences Announces Completion Of Patient Enrollment In Phase 2B 'Fascinate-2' Clinical Trial

Reuters · 09/13/2022 09:31
BRIEF-Sagimet Biosciences Announces Completion Of Patient Enrollment In Phase 2B 'Fascinate-2' Clinical Trial

- Sagimet Biosciences Inc SGMT.O:

  • SAGIMET BIOSCIENCES ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2B 'FASCINATE-2' CLINICAL TRIAL WITH DENIFANSTAT (TVB-2640), A FIRST-IN-CLASS FATTY ACID SYNTHASE INHIBITOR, IN NON-ALCOHOLIC STEATOHEPATITIS

  • SAGIMET BIOSCIENCES INC - ANTICIPATES SHARING TOP-LINE LIVER BIOPSY DATA IN Q4 OF 2023

Source text for Eikon: ID:

Further company coverage: SGMT.O


((reuters.briefs@thomsonreuters.com;))